{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:15:17Z","timestamp":1760148917533,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>(1) Background: direct-acting antivirals (DAA) are the current standard of care for chronic hepatitis C. Oncologic patients remain among the most difficult-to-treat subgroups of hepatitis C virus (HCV)-infected patients due to their clinical frailty and complex therapeutic protocols received. (2) Methods: we retrospectively collected and analysed clinical data of 30 consecutive patients treated with DAA, between 2015 and 2022, for chronic HCV infection in the context of oncologic disease. (3) Results: most patients were females (63.3%), median age was 67 years, HCV genotype 1 was prevalent (60%), and median HCV RNA levels were 2.2 \u00d7 106 IU\/mL. The most common malignancy was breast cancer (37%), and the chief oncologic drugs co-administered with DAAs were tamoxifen, platinum derivatives, cyclophosphamide, paclitaxel, rituximab and doxorubicin. Overall, 50% of patients had chronic hepatitis. A total of 76.7% underwent a sofosbuvir-based treatment. Sustained virological response 12 weeks after the end of therapy (SVR12) was reached in all patients. After SVR12, two patients died. DAA treatment was well tolerated; no patients had to stop DAA treatment or showed any adverse event or drug-drug interaction specifically attributable to DAAs. (4) Conclusions: DAA treatment should be promptly offered to oncologic patients with chronic hepatitis C in order to achieve aminotransferase normalization and viremia control, making antineoplastic therapy feasible and safe.<\/jats:p>","DOI":"10.3390\/pathogens11080860","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T04:04:00Z","timestamp":1659326640000},"page":"860","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of Direct Antiviral Agents for Hepatitis C in Patients with Malignancies Other Than Liver Cancer: A Case Series"],"prefix":"10.3390","volume":"11","author":[{"given":"Fabian","family":"Patauner","sequence":"first","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Stanzione","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Public Medicine, Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80138 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranca","family":"Stornaiuolo","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Public Medicine, Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80138 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Martone","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Palladino","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Public Medicine, Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80138 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-4949","authenticated-orcid":false,"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[{"name":"Department of Mental Health and Public Medicine, Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80138 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5381-3537","authenticated-orcid":false,"given":"Emanuele","family":"Durante-Mangoni","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Napoli, Italy"},{"name":"Unit of Infectious and Transplant Medicine, AORN Ospedali Dei Colli-Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Zampino","sequence":"additional","affiliation":[{"name":"Department of Advanced Medical and Surgical Sciences, University of Campania Luigi Vanvitelli, 80138 Napoli, Italy"},{"name":"Unit of Infectious and Transplant Medicine, AORN Ospedali Dei Colli-Monaldi Hospital, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218.","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jvh.12875","article-title":"Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe","volume":"25","author":"Papatheodoridis","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4103\/IJPM.IJPM_240_17","article-title":"Incidentally detected asymptomatic hepatitis C virus infection with significant fibrosis: Possible impacts on management","volume":"61","author":"Gupta","year":"2018","journal-title":"Indian J. Pathol. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.amjmed.2014.10.004","article-title":"Screening, diagnosis, treatment, and management of hepatitis C: A novel, comprehensive, online resource center for primary care providers and specialists","volume":"127","author":"Lebovics","year":"2014","journal-title":"Am. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ygh2.456","article-title":"Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with direct-acting antivirals","volume":"3","author":"Lybeck","year":"2021","journal-title":"GastroHep"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/jgh3.12294","article-title":"Salvage therapy in cancer patients with hepatitis C without sustained virologic response after direct-acting antivirals-A prospective study","volume":"4","author":"Pritchard","year":"2019","journal-title":"JGH Open."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","article-title":"Direct antiviral agents (DAAs)\u2014A new age in the treatment of hepatitis C virus infection","volume":"183","author":"Spengler","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e000943","DOI":"10.1136\/jitc-2020-000943","article-title":"Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy","volume":"8","author":"Ziogas","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3322\/caac.21403","article-title":"The oncologic burden of hepatitis C virus infection: A clinical perspective","volume":"67","author":"Torres","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/apt.13825","article-title":"Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer","volume":"44","author":"Economides","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.29364","article-title":"Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma","volume":"67","author":"Persico","year":"2018","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.23736\/S2724-5985.21.02834-8","article-title":"Impact of direct antiviral agents (DAAs) on B-cell non-Hodgkin\u2019s lymphoma in patients with chronic hepatitis C","volume":"67","author":"Ciancio","year":"2021","journal-title":"Minerva Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1111\/liv.12897","article-title":"HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents","volume":"35","author":"Carrier","year":"2015","journal-title":"Liver Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/liv.14119","article-title":"Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: A systematic review and meta-analysis","volume":"39","author":"Masarone","year":"2019","journal-title":"Liver Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Global Burden Of Hepatitis C Working Group (2004). Global burden of disease (GBD) for hepatitis C. J. Clin. Pharmacol., 44, 20\u201329.","DOI":"10.1177\/0091270003258669"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Khatun, M., and Ray, R.B. (2019). Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells, 8.","DOI":"10.3390\/cells8101249"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus (HCV) infection","volume":"3","author":"Chen","year":"2006","journal-title":"Int. J. Med. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"European Association for Study of Liver (2015). EASL Recommendations on Treatment of Hepatitis C 2015. J. Hepatol., 63, 199\u2013236.","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL Recommendations on Treatment of Hepatitis C 2016. J. Hepatol., 66, 153\u2013194.","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2018). EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol., 69, 461\u2013511.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nevola, R., Messina, V., Marrone, A., Coppola, N., Rescigno, C., Esposito, V., Sangiovanni, V., Claar, E., Pisaturo, M., and Fusco, F.M. (2022). Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic-Standardized National Screening or One Tailored to Local Epidemiology?. Biology, 11.","DOI":"10.3390\/biology11040609"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1634\/theoncologist.2020-0172","article-title":"Hepatitis C Virus Infection and Chemotherapy in Breast Cancer: A Retrospective Chart Analysis","volume":"25","author":"Ghosh","year":"2020","journal-title":"Oncologist"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2016-05-718643","article-title":"How I treat hepatitis C virus infection in patients with hematologic malignancies","volume":"128","author":"Torres","year":"2016","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.seminoncol.2005.11.002","article-title":"Hepatotoxicity of chemotherapy","volume":"33","author":"Floyd","year":"2006","journal-title":"Semin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41395-018-0383-2","article-title":"Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study","volume":"114","author":"Torres","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.14309\/ajg.0000000000000095","article-title":"Virus: No Longer a Barrier to Oncology Care","volume":"114","author":"Laique","year":"2019","journal-title":"Am. J. Gastroenterol."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/8\/860\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:59:36Z","timestamp":1760140776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/8\/860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":27,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["pathogens11080860"],"URL":"https:\/\/doi.org\/10.3390\/pathogens11080860","relation":{},"ISSN":["2076-0817"],"issn-type":[{"type":"electronic","value":"2076-0817"}],"subject":[],"published":{"date-parts":[[2022,7,29]]}}}